Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total value of $507,592.98. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, January 21st, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $97.63, for a total value of $420,004.26.

Palvella Therapeutics Price Performance

NASDAQ PVLA opened at $112.50 on Friday. The firm has a market capitalization of $1.33 billion, a P/E ratio of -42.78 and a beta of -0.30. Palvella Therapeutics, Inc. has a 1-year low of $18.23 and a 1-year high of $151.18. The business’s 50-day simple moving average is $103.11 and its 200-day simple moving average is $88.43.

Institutional Trading of Palvella Therapeutics

Several large investors have recently bought and sold shares of the company. Federated Hermes Inc. purchased a new stake in shares of Palvella Therapeutics during the third quarter worth about $21,255,000. Aspiriant LLC purchased a new position in Palvella Therapeutics in the third quarter valued at about $367,000. Aberdeen Group plc acquired a new stake in Palvella Therapeutics during the 3rd quarter valued at approximately $3,212,000. Frazier Life Sciences Management L.P. increased its holdings in Palvella Therapeutics by 4.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after purchasing an additional 32,388 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Palvella Therapeutics during the 2nd quarter worth approximately $399,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Canaccord Genuity Group lifted their price target on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Chardan Capital restated a “buy” rating and set a $210.00 target price on shares of Palvella Therapeutics in a report on Monday, March 16th. HC Wainwright upped their price target on shares of Palvella Therapeutics from $200.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Palvella Therapeutics in a report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $184.87.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.